C4 Therapeutics, Inc. Adjustments to Additional Paid in Capital, Other
C4 Therapeutics, Inc. (CCCC) reported Adjustments to Additional Paid in Capital, Other of $14.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalOther · last filed 2026-08-11
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2026-06-30 was $14.00K, a 44.00% decline year-over-year.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2026-03-31 was $28.00K, a 12.00% increase year-over-year.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2025-09-30 was $27.00K, a 15.63% decline year-over-year.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for the quarter ending 2025-06-30 was $25.00K, a 30.56% decline year-over-year.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2025 was $103.00K, a 930.00% increase from fiscal 2024.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2024 was $10.00K, a 92.81% decline from fiscal 2023.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2023 was $139.00K, a 12.03% decline from fiscal 2022.
- C4 Therapeutics, Inc. adjustments to additional paid in capital, other for fiscal 2022 was $158.00K, a 12.22% decline from fiscal 2021.
| Period end | Adjustments to Additional Paid in Capital, Other 3 month | Adjustments to Additional Paid in Capital, Other 6 month | Adjustments to Additional Paid in Capital, Other 9 month | Adjustments to Additional Paid in Capital, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.00K 10-Q · filed 2026-08-11 | $42.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $28.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $103.00K 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $27.00K 10-Q · filed 2025-11-06 | $52.00K derived: sum of 2 quarters · filed 2026-08-11 | $77.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $25.00K 10-Q · filed 2026-08-11 | $50.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $25.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $10.00K 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $32.00K 10-Q · filed 2025-11-06 | $68.00K derived: sum of 2 quarters · filed 2025-11-06 | $52.00K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $36.00K 10-Q · filed 2025-11-06 | $20.00K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | -$16.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $139.00K 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $36.00K 10-Q · filed 2024-10-31 | $72.00K derived: sum of 2 quarters · filed 2024-10-31 | $104.00K derived: sum of 3 quarters · filed 2024-10-31 | |
| 2023-06-30 | $36.00K 10-Q · filed 2024-10-31 | $68.00K derived: sum of 2 quarters · filed 2024-10-31 | ||
| 2023-03-31 | $32.00K 10-Q · filed 2024-10-31 | |||
| 2022-12-31 | $158.00K 10-K · filed 2024-02-22 | |||
| 2022-09-30 | $31.00K 10-Q · filed 2023-11-01 | $70.00K derived: sum of 2 quarters · filed 2023-11-01 | $129.00K derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $39.00K 10-Q · filed 2023-11-01 | $98.00K derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $59.00K 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $180.00K 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $222.00K 10-Q · filed 2022-11-03 | $302.00K derived: sum of 2 quarters · filed 2022-11-03 | $283.00K derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $80.00K 10-Q · filed 2022-11-03 | $61.00K derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | -$19.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |